TY - JOUR
T1 - The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma
AU - Kraft, Monica
AU - Wenzel, Sally E.
AU - Bettinger, Charlotte M.
AU - Martin, Richard J.
N1 - Funding Information:
Supported by grants from the Glaxo-Wellcome Company and the Parker B. Francis Foundation.
PY - 1997
Y1 - 1997
N2 - Study objective: To determine the efficacy of salmeterol alone in a group of patients with moderate asthma with nocturnal worsening of symptoms. Design: Double-blind, randomized, placebo-controlled crossover study. Setting: Tertiary care hospital specializing in respiratory diseases. Participants: Ten patients with nocturnal asthma. Interventions: Subjects were randomized to salmeterol, 100 μg twice daily, or placebo for 6 weeks with a 1-week washout between treatment periods. Symptoms, nocturnal awakenings, and β2-agonist use were recorded daily. Spirometry was performed at weeks 1 and 6 of each period at bedtime and at 4 AM, and methacholine challenge was performed at 4 AM followed by bronchoscopy with BAL. BAL fluid analysis included cell count and differential count, eosinophil cationic protein Charcot-Leyden crystal protein, leukotriene B4, and thromhoxane B2. Results: The percentage of nights with awakenings decreased significantly with salmeterol (69.8 ± 8.7% vs 30.6 ± 10.8% for placebo and salmeterol respectively p=0.02). The percentage of 24-h days with supplemental inhaled β2-agonist use significantly decreased with salmeterol (85.9 ± 9.4% vs 70.4 ± 10.1% for placebo and salmeterol, respectively; p=0.04). There were no significant differences in bronchial reactivity, 4 AM FEV1, overnight percentage change in FEV1, or indexes of airway inflammation. Conclusions: Salmeterol alone improves the number of nocturnal awakenings and supplemental 24-h β2-agonist use in nocturnal asthma without significantly altering lung function and airway inflammation.
AB - Study objective: To determine the efficacy of salmeterol alone in a group of patients with moderate asthma with nocturnal worsening of symptoms. Design: Double-blind, randomized, placebo-controlled crossover study. Setting: Tertiary care hospital specializing in respiratory diseases. Participants: Ten patients with nocturnal asthma. Interventions: Subjects were randomized to salmeterol, 100 μg twice daily, or placebo for 6 weeks with a 1-week washout between treatment periods. Symptoms, nocturnal awakenings, and β2-agonist use were recorded daily. Spirometry was performed at weeks 1 and 6 of each period at bedtime and at 4 AM, and methacholine challenge was performed at 4 AM followed by bronchoscopy with BAL. BAL fluid analysis included cell count and differential count, eosinophil cationic protein Charcot-Leyden crystal protein, leukotriene B4, and thromhoxane B2. Results: The percentage of nights with awakenings decreased significantly with salmeterol (69.8 ± 8.7% vs 30.6 ± 10.8% for placebo and salmeterol respectively p=0.02). The percentage of 24-h days with supplemental inhaled β2-agonist use significantly decreased with salmeterol (85.9 ± 9.4% vs 70.4 ± 10.1% for placebo and salmeterol, respectively; p=0.04). There were no significant differences in bronchial reactivity, 4 AM FEV1, overnight percentage change in FEV1, or indexes of airway inflammation. Conclusions: Salmeterol alone improves the number of nocturnal awakenings and supplemental 24-h β2-agonist use in nocturnal asthma without significantly altering lung function and airway inflammation.
KW - inflammation
KW - nocturnal asthma
KW - salmeterol
UR - http://www.scopus.com/inward/record.url?scp=0031005429&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031005429&partnerID=8YFLogxK
U2 - 10.1378/chest.111.5.1249
DO - 10.1378/chest.111.5.1249
M3 - Article
C2 - 9149578
AN - SCOPUS:0031005429
SN - 0012-3692
VL - 111
SP - 1249
EP - 1254
JO - CHEST
JF - CHEST
IS - 5
ER -